Lysergide - PharmaKB

Lysergide

Lysergide is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C, and 5-hydroxytryptamine receptor 1A.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

No data

Clinical

Clinical Trials

71 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Acute coronary syndrome	D054058	EFO_0005672	—	—	—	—	1	—	1
Cardiogenic shock	D012770	—	R57.0	—	—	—	1	—	1
Low cardiac output	D002303	—	—	—	—	—	1	—	1
Pulmonary edema	D011654	EFO_1001134	J81	—	—	—	1	—	1

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Lysosomal storage diseases	D016464	—	—	4	6	1	—	3	11
Mucopolysaccharidosis iv	D009085	—	E76.210	2	5	2	—	2	9
Major depressive disorder	D003865	EFO_0003761	F22	1	1	1	—	3	6
Anxiety disorders	D001008	EFO_0006788	F41.1	—	2	2	—	1	5
Mucopolysaccharidoses	D009083	—	E76.3	1	1	1	—	1	3
Generalized anxiety disorder	D000098647	—	—	—	1	2	—	—	3
Intracranial hypertension	D019586	EFO_1000992	—	—	—	1	—	—	1

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Depression	D003863	—	F33.9	1	1	—	—	2	4
Syndrome	D013577	—	—	1	2	—	—	2	4
Depressive disorder	D003866	EFO_1002014	F32.A	1	1	—	—	1	3
Mucopolysaccharidosis iii	D009084	—	E76.22	2	3	—	—	—	3
Multiple myeloma	D009101	—	C90.0	1	2	—	—	—	2
Plasma cell neoplasms	D054219	—	—	1	2	—	—	—	2
Headache	D006261	—	R51	—	2	—	—	—	2
Cluster headache	D003027	—	G44.00	—	2	—	—	—	2
Anxiety	D001007	EFO_0005230	F41.1	—	2	—	—	—	2
Alcoholism	D000437	EFO_0003829	F10.1	—	1	—	—	1	2

Show 12 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	18	—	—	—	2	20
Fabry disease	D000795	Orphanet_324	E75.21	1	—	—	—	1	2
Rheumatoid arthritis	D001172	EFO_0000685	M06.9	1	—	—	—	—	1
Systemic lupus erythematosus	D008180	EFO_0002690	M32	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Niemann-pick diseases	D009542	—	E75.24	—	—	—	—	2	2
Type a niemann-pick disease	D052536	EFO_1001380	E75.240	—	—	—	—	2	2
Frontotemporal dementia	D057180	—	G31.0	—	—	—	—	2	2
Type c niemann-pick disease	D052556	Orphanet_646	E75.242	—	—	—	—	2	2
Primary progressive aphasia	D018888	EFO_0009053	G31.01	—	—	—	—	2	2
Pick disease of the brain	D020774	EFO_0003096	G31.01	—	—	—	—	2	2
Personality disorders	D010554	—	F60.6	—	—	—	—	2	2
Substance-related disorders	D019966	EFO_0003890	F13	—	—	—	—	2	2
Post-traumatic stress disorders	D013313	EFO_0001358	F43.1	—	—	—	—	2	2
Dementia	D003704	EFO_0003862	F03	—	—	—	—	1	1

Show 18 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Lysergide
INN	lysergide
Description	Lysergic acid diethylamide is an ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine. It has a role as a hallucinogen, a serotonergic agonist and a dopamine agonist. It is an ergoline alkaloid, an organic heterotetracyclic compound and a monocarboxylic acid amide. It is functionally related to a lysergamide.
Classification	Small molecule
Drug class	ergot alkaloid deriviatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1